Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 984 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vaccine placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

NCT03172975
View directory record Official record
Conditions
Hookworm Infections
Interventions
Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF, Placebo, Albendazole, Necator americanus Larval Inoculum
Biological · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 6, 2026, 2:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 6, 2026, 2:45 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 6, 2026, 2:45 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

NCT01139437
View directory record Official record
Conditions
Human Parainfluenza Virus 2
Interventions
Standard Dose HPIV2 Vaccine, Low dose HPIV2 vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults

NCT00819013
View directory record Official record
Conditions
Influenza
Interventions
Influenza A Vaccine: ACAM FLU-A, Saline placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

NCT02097589
View directory record Official record
Conditions
Healthy Controls
Interventions
Atorvastatin, Pneumovax 23, Placebo (lactose pill)
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00252148
View directory record Official record
Conditions
HIV Infection
Interventions
ADMVA
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 6, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stories to Prevent (StoP) HPV Cancers

NCT06808776
View directory record Official record
Conditions
Human Papillomavirus Vaccination, Emotions
Interventions
Cancer survivor narrative, Healthy eating tips
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 6, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 6, 2026, 2:45 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

NCT00508651
View directory record Official record
Conditions
Healthy
Interventions
MEDI-560, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Madera, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2011 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

NCT05027932
View directory record Official record
Conditions
Influenza
Interventions
IN Placebo, IM Placebo, BPL-1357
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632
View directory record Official record
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811
View directory record Official record
Conditions
Influenza Infection
Interventions
VAX102 [Flagellin.HuM2e], Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Lenexa, Kansas • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760
View directory record Official record
Conditions
HIV Infections
Interventions
Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant, Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
Biological
Lead sponsor
Madhu Chhanda Choudhary
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 6, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions
Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
12 Months to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newton, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 6, 2026, 2:45 PM EDT